CRISPR Therapeutics AG

BRSE:1CG Stock Report

Market Cap: CHF 4.1b

CRISPR Therapeutics Valuation

Is 1CG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1CG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CHF 115.33
Fair Value
58.4% undervalued intrinsic discount
25
Number of Analysts

Below Fair Value: 1CG (CHF48.02) is trading below our estimate of fair value (CHF115.33)

Significantly Below Fair Value: 1CG is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1CG?

Key metric: As 1CG barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 1CG. This is calculated by dividing 1CG's market cap by their current book value.
What is 1CG's PB Ratio?
PB Ratio2.3x
BookUS$1.93b
Market CapUS$4.48b

Price to Book Ratio vs Peers

How does 1CG's PB Ratio compare to its peers?

The above table shows the PB ratio for 1CG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5.9x
MOLN Molecular Partners
1.2x-9.2%CHF 166.5m
BSLN Basilea Pharmaceutica
6.6x6.5%CHF 534.6m
KURN Kuros Biosciences
14.9xn/aCHF 898.8m
RLF Relief Therapeutics Holding
0.8xn/aCHF 41.3m
1CG CRISPR Therapeutics
2.3x47.8%CHF 4.5b

Price-To-Book vs Peers: 1CG is good value based on its Price-To-Book Ratio (2.3x) compared to the peer average (12.2x).

Price to Book Ratio vs Industry

How does 1CG's PB Ratio compare vs other companies in the European Biotechs Industry?

22 CompaniesPrice / BookEstimated GrowthMarket Cap
1CG 2.3xIndustry Avg. 2.4xNo. of Companies22PB01.63.24.86.48+
22 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 1CG is good value based on its Price-To-Book Ratio (2.3x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 1CG's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1CG PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 1CG's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1CG forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 48.02
CHF 75.21
+56.6%
53.6%CHF 241.11CHF 28.79n/a25
Feb ’26n/a
CHF 75.30
0%
54.5%CHF 241.69CHF 27.06n/a24
Jan ’26n/a
CHF 72.18
0%
41.6%CHF 175.71CHF 26.49n/a24
Dec ’25n/a
CHF 72.51
0%
41.6%CHF 176.51CHF 26.61n/a24
Nov ’25n/a
CHF 71.40
0%
41.6%CHF 170.84CHF 25.75n/a24
Oct ’25CHF 39.49
CHF 72.34
+83.2%
41.2%CHF 172.49CHF 26.00n/a24
Sep ’25CHF 40.55
CHF 72.34
+78.4%
41.2%CHF 172.49CHF 26.00n/a24
Aug ’25CHF 51.99
CHF 79.22
+52.4%
40.0%CHF 182.17CHF 27.46n/a24
Jul ’25CHF 49.09
CHF 79.22
+61.4%
40.0%CHF 182.17CHF 27.46n/a24
Jun ’25CHF 53.49
CHF 79.22
+48.1%
40.0%CHF 182.17CHF 27.46n/a24
May ’25CHF 49.99
CHF 80.41
+60.8%
39.0%CHF 181.58CHF 27.37n/a24
Apr ’25CHF 62.45
CHF 78.23
+25.3%
39.0%CHF 176.75CHF 26.65n/a24
Mar ’25CHF 76.34
CHF 76.92
+0.8%
39.3%CHF 175.35CHF 26.43n/a24
Feb ’25CHF 54.55
CHF 74.87
+37.3%
44.1%CHF 171.42CHF 25.84n/a24
Jan ’25CHF 55.84
CHF 73.73
+32.1%
43.3%CHF 161.82CHF 25.82n/a25
Dec ’24CHF 57.42
CHF 79.69
+38.8%
48.7%CHF 198.41CHF 37.88n/a24
Nov ’24CHF 39.87
CHF 80.52
+101.9%
48.1%CHF 199.72CHF 39.04n/a24
Oct ’24CHF 41.12
CHF 79.55
+93.5%
45.0%CHF 202.60CHF 39.60CHF 39.4925
Sep ’24CHF 43.85
CHF 76.09
+73.5%
48.0%CHF 193.29CHF 37.78CHF 40.5526
Aug ’24CHF 49.02
CHF 73.06
+49.0%
45.2%CHF 189.21CHF 36.12CHF 51.9927
Jul ’24CHF 50.33
CHF 76.61
+52.2%
45.5%CHF 198.83CHF 37.96CHF 49.0927
Jun ’24CHF 58.64
CHF 76.72
+30.8%
45.4%CHF 199.35CHF 38.06CHF 53.4927
May ’24CHF 45.41
CHF 76.33
+68.1%
46.9%CHF 196.63CHF 34.86CHF 49.9925
Apr ’24n/a
CHF 79.30
0%
46.3%CHF 201.25CHF 35.68CHF 62.4525
Mar ’24n/a
CHF 86.11
0%
43.7%CHF 206.99CHF 36.69CHF 76.3423
Feb ’24n/a
CHF 88.82
0%
42.4%CHF 201.45CHF 33.88CHF 54.5523
Analyst Price Target
Consensus Narrative from 25 Analysts
CHF 76.88
Fair Value
37.5% undervalued intrinsic discount
25
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/19 02:13
End of Day Share Price 2025/02/19 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CRISPR Therapeutics AG is covered by 45 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Huidong WangBarclays
Konstantinos BiliourisBMO Capital Markets Equity Research